Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Acknowledgments br References br HER FISH pharmDx Interpr

    2020-08-18


    Acknowledgments
    References
    HER2 FISH pharmDx. (2014). Interpretation guide—Breast cancer. Carpinteria, CADako: Dako manual.
    Hsu, W. Y. (2012). Improved watershed transform for tumor segmentation: Applica-tion to mammogram image compression. Expert Systems with Applications, 39(4), 3950–3955.
    Gong, Y., Gilcrease, M., & Sneige, N. (2005). Reliability of chromogenic in situ hy-bridization for detecting HER2 gene status in breast cancer: Comparison with FISH and assessment of interobserver reproducibility. Modern Pathology, 18(8), 1015–1021.
    Kostopoulos, I. (2005). Automated evaluation of Her-2/neu status in breast tis-sue from fluorescent in situ hybridization images. IEEE Transactions on Image Processing, 14(9), 1288–1299.
    Soille, P. (2003). Morphological image analysis, principles and applications. Berlin:
    Springer.
    Theodosiou, Z., Kasampalidis, I. J., & Karayannopoulou, G. (2008). Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. Breast, 17(1), 82–86.
    WHO Cancer mortality database (IARC) (2018). International agency for research on cancer, http://www-dep.iarc.fr/WHOdb/WHOdb.htm/.
    Wolff, A. C., Hammond, M. E., Hicks, D., Dowsett, M., McShane, L., Allison, K., et al. (2014). Recommendations for human epidermal growth factor Necrostatin1 2 testing in breast cancer, American Society of Clinical Oncology/College of Ameri-can Pathologists, Clinical Practice Guideline Update. Archives of Pathology & Lab-oratory Medicine, 138(2), 242–256.
    Contents lists available at ScienceDirect
    European Journal of Pharmaceutical Sciences
    journal homepage: www.elsevier.com/locate/ejps
    Autophagy as a molecular target for cancer treatment 
    T
    Nur Mehpare Kocaturka, Yunus Akkocb, Cenk Kigc, Oznur Bayraktard, Devrim Gozuacika,b, Ozlem Kutlua,
    a Sabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul 34956, Turkey
    b Faculty of Engineering and Natural Sciences, Molecular Biology, Genetics and Bioengineering Program, Sabanci University, Istanbul 34956, Turkey
    c Faculty of Medicine, Istanbul Yeni Yuzyil University, Zeytinburnu, 34010 Istanbul, Turkey
    d Faculty of Medicine, Department of Medical Biology and Genetic, Okan University, Istanbul, Turkey
    Chemical compounds studied in this article:
    Epigallocatechin gallate (EGCG) (PubChem CID: 65064)
    Hidroxychloroquine (PubChem CID: 3652)
    Suberoylanilide Hydroxamic acid (SAHA)
    Autophagy is an evolutionarily conserved catabolic mechanism, by which eukaryotic cells recycle or degrades internal constituents through membrane-trafficking pathway. Thus, autophagy provides the cells with a sus-tainable source of biomolecules and energy for the maintenance of homeostasis under stressful conditions such as tumor microenvironment. Recent findings revealed a close relationship between autophagy and malignant transformation. However, due to the complex dual role of autophagy in tumor survival or cell death, efforts to develop efficient treatment strategies targeting the autophagy/cancer relation have largely been unsuccessful. Here we review the two-faced role of autophagy in cancer as a tumor suppressor or as a pro-oncogenic me-chanism. In this sense, we also review the shared regulatory pathways that play a role in autophagy and ma-lignant transformation. Finally, anti-cancer therapeutic agents used as either inhibitors or inducers of autophagy have been discussed.
    Corresponding author at: Sabanci University Nanotechnology Research and Application Center (SUNUM), Orta Mah. Univ. Cad. No: 27, Istanbul 34956, Turkey. E-mail address: [email protected] (O. Kutlu).
    Keywords:
    Autophagy
    Cancer
    Therapeutic agents
    1. Introduction
    Autophagy is a catabolic process in which cytoplasmic materials are directed to the lysosomes for degradation. This process is evolutionarily conserved from yeast to man and its activity is required for maintaining cellular homeostasis through elimination of dysfunctional organelles, protein aggregates or even long-lived proteins. So far, three main classes of autophagy have been identified: Macroautophagy, micro-autophagy and chaperon-mediated autophagy (CMA). Macroautophagy (autophagy herein) is the main pathway that is devided into bulk and
    selective autophagy according to the specificity of targeted cytoplasmic constituents. In bulk autophagy, degradation targets are mainly wrapped within a double-membraned vesicle (autophagosome) as portions of cytoplasm in a non-selective manner. On the other hand, in selective autophagy particular substrate such as mitochondria (Okamoto et al., 2009), peroxisomes (Till et al., 2012), lysosomes (Hung et al., 2013), ER (Khaminets et al., 2015), ribosomes (An and Harper, 2018), lipid droplets (Onal et al., 2017), pathogenic in-tracellular invaders (Wileman, 2013) and even certain free proteins and RNAs (Huang et al., 2014b) are targeted into the autophagosome. In